New York–based hematologist-oncologist and clinical researcher works to lower the barriers to enrolling in clinical trials.

Vimentin is a type III intermediate filament (IF) protein typically expressed in cells that differentiate into connective ...

Doctors are enrolling patients in a groundbreaking clinical trial aimed at reducing cancer recurrence in patients with ...

Members of the Leukemia and Lymphoma Society discussed the importance of educating others, fundraising and spreading ...

A research team has made a major discovery on how the CUL5 gene affects CAR-T cell therapy, an advanced cancer therapy. The study reveals that reducing the activity of the CUL5 gene helps CAR-T cells ...

Northwestern Medicine scientists have uncovered a key pathway controlling tumor growth in B-cell lymphomas, according to a ...